243 related articles for article (PubMed ID: 27865464)
1. Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.
Reuther GW
Prog Mol Biol Transl Sci; 2016; 144():437-484. PubMed ID: 27865464
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of myeloproliferative neoplasms.
Skoda RC; Duek A; Grisouard J
Exp Hematol; 2015 Aug; 43(8):599-608. PubMed ID: 26209551
[TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
4. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
5. [Molecularly pathogenesis and molecular targeted therapy for myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2015 Feb; 56(2):150-8. PubMed ID: 25765794
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
Front Immunol; 2020; 11():604142. PubMed ID: 33329600
[TBL] [Abstract][Full Text] [Related]
7. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies].
Takenaka K
Rinsho Ketsueki; 2016; 57(10):1944-1955. PubMed ID: 27725592
[TBL] [Abstract][Full Text] [Related]
8. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
9. [Effect of mutation on diagnosis, risk stratification, and treatment decisions in Philadelphia-negative myeloproliferative neoplasms].
Kirito K
Rinsho Ketsueki; 2017; 58(10):1931-1940. PubMed ID: 28978835
[TBL] [Abstract][Full Text] [Related]
10. Genomics of MPN progression.
Patel AA; Odenike O
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):440-449. PubMed ID: 33275731
[TBL] [Abstract][Full Text] [Related]
11. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
[TBL] [Abstract][Full Text] [Related]
12. [Gene mutations in myeloproliferative neoplasms].
Araki M; Morishita S; Komatsu N
Rinsho Ketsueki; 2016; 57(12):2526-2534. PubMed ID: 28090022
[TBL] [Abstract][Full Text] [Related]
13. Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.
Pandey R; Kapur R
Mol Cancer; 2015 Jun; 14():118. PubMed ID: 26062813
[TBL] [Abstract][Full Text] [Related]
14. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
15. Advances in understanding the pathogenesis of familial myeloproliferative neoplasms.
Rumi E; Cazzola M
Br J Haematol; 2017 Sep; 178(5):689-698. PubMed ID: 28444727
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
17. JAK2
Lin CH; Kaushansky K; Zhan H
Blood Cells Mol Dis; 2016 Nov; 62():42-48. PubMed ID: 27865175
[TBL] [Abstract][Full Text] [Related]
18. The evolving genomic landscape of myeloproliferative neoplasms.
Nangalia J; Green TR
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):287-96. PubMed ID: 25696868
[TBL] [Abstract][Full Text] [Related]
19. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?
Chen E; Mullally A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):268-76. PubMed ID: 25696866
[TBL] [Abstract][Full Text] [Related]
20. Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.
Magor GW; Tallack MR; Klose NM; Taylor D; Korbie D; Mollee P; Trau M; Perkins AC
J Mol Diagn; 2016 Sep; 18(5):707-718. PubMed ID: 27449473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
